Inovio Pharmaceuticals Completes PENNVAX-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses
Significant T-cell responses demonstrate potential of HIVsynthetic immunogen delivered using electroporation BLUE BELL, Pa., Sept. 14, 2011 /PRNewswire/ — InovioPharmaceuticals, Inc. (NYSE Amex: INO), a leader in the developmentof…
September 14th, 2011
Posted in
Drug